Innovative Therapeutics in Oncology and Neuroscience
Efgartigimod
Phase 3 ADAPT+ Study Showed Consistent and Repeatable Improvement in
Both MG-ADL and QMG Scores Over Multiple Cycles
Mean change (±SE) in MG-ADL total score
2
C
+
6
-8
-10
CMI
MG-ADL Total Score
Mean Change from Cycle Baseline by Cycle 1
Week 3 of Cycle 1:
Mean change [SE]: -5.0 [0.33]
Week 012
3
7
Efg Dosing
ADAPT+
n
Cycle
1
111
2
101
3
91
456981
82
74
73
7
59
55
47
10
40
11
11
Mean change (±SE) in MG-ADL total score
2
6
QMG Total Score
Mean Change from Cycle Baseline by Cycle 2
Week 3 of Cycle 1:
Mean change [SE]: -4.7 [0.41]
-8
11
Week 012
Efg Dosing
3
38
Abbreviations: clinical meaningful improvement (CMI), treatment (TX).
Note: (1) Only cycles with data out to week 11 are depicted; (2) QMG was not a required assessment in part B of ADAPT+; therefore, there are fewer data for cycle compared to MG-ADL.
7
ADAPT+
Cycle
n
1
111
2
3
87
4567
56
49
32
RESYOO:
99
70
Approved
11
Clinical Data -
AutoimmuneView entire presentation